Taysha Gene Therapies, Inc.
TSHA
Jodie situation report
Taysha Gene Therapies, Inc.'s move is being confirmed by its market group.
No new filing conclusion is available. 28 of 31 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 2 directly disclosed connections are confirming.
- At least 21 of 31 members remain active in the next snapshot.
- Capital-flow agreement rises above 55%.
- A filing-linked outsider such as NRIX begins moving with the group.
Invalidation: The live read weakens if participation falls to 10 of 31 members or fewer.
Who this business touches
The relationships behind TSHA
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
TRINTrinity Capital Inc.lenderMay 6, 2026 ▾
“Note 7 – Term Loans 2025 Loan with Trinity Capital On August 7, 2025 (the “Trinity Refinance Date”), the Company entered into a Loan and Security Agreement (the “2025 Trinity Term Loan Agreement”), by and among the Company, the lenders party thereto from time…”
Depended on by
RGNXREGENXBIO Inc.competitorMar 5, 2026 ▾
“Competition We are aware of a number of companies focused on developing and commercializing gene therapies in various disease indications, including 4D Molecular Therapeutics, Inc., Amicus Therapeutics, Inc., Astellas Pharma, BioMarin Pharmaceutical, Inc., Li…”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 2 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
TSHA is currently a Participant in the organic co-movement group Biotechnology Therapeutics. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 2 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.